MimiVax Overview

  • Founded
  • 2012

  • Status
  • Private

  • Employees
  • 3

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $5M

  • Investors
  • 4

MimiVax General Information


Developer of immunotherapeutic vaccines and targeted therapies intended to control tumor growth and recurrence. The company's vaccines use survivin-targeting technology to target a cell-survival protein present in most cancers, enabling healthcare providers to disrupt cancer, cure patients and increase patient survival rates.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Elm & Carlton Streets
  • Buffalo, NY 14263
  • United States
+1 (716) 000-0000

MimiVax Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MimiVax Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 10-Dec-2021 $5M 0000 Completed Generating Revenue
6. Later Stage VC 24-Jun-2020 000 0000 Completed Clinical Trials - Phase 2
5. Later Stage VC 02-Aug-2019 0000 Cancelled Clinical Trials - Phase 2
4. Early Stage VC 000 000 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series A) 25-Aug-2015 00.000 000 Completed Startup
2. Grant 01-Mar-2015 $2M $450K Completed Startup
1. Seed Round 01-Jan-2012 $450K $450K Completed Startup
To view MimiVax’s complete valuation and funding history, request access »

MimiVax Executive Team (4)

Name Title Board Seat Contact Info
Michael Ciesielski Ph.D Co-Founder, Chief Executive Officer & Chief Scientific Officer
Robert Fenstermaker MD Co-Founder & Chief Medical Officer
Anil Goyal Ph.D Chief Business Officer
Scott Friedman JD Co-Founder, General Counsel & Board Member
To view MimiVax’s complete executive team members history, request access »

MimiVax Board Members (4)

Name Representing Role Since
David Hohn MD Self Board Member 000 0000
Doug Plessinger Self Board Member 000 0000
Jeremy Jacobs Jr. Buffalo Capital Partners Chairman 000 0000
Scott Friedman JD Self Co-Founder, General Counsel & Board Member 000 0000
To view MimiVax’s complete board members history, request access »

MimiVax Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MimiVax Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Jerry Jacobs Angel (individual) Minority 000 0000 000000 0
Varia Ventures Venture Capital Minority 000 0000 000000 0
Buffalo Capital Partners Impact Investing Minority 000 0000 000000 0
Roswell Park Cancer Institute Corporation Minority 000 0000 000000 0
To view MimiVax’s complete investors history, request access »